

Lupin signs distribution agreement with Medis for orphan drug NaMuscla

09 February 2022 | News

The agreement enables expanded patient access to the only EU-approved treatment for myotonia symptoms in nondystrophic myotonic disorders in Central and Eastern European territories



Lupin has entered into a distribution agreement with Medis for Lupin's orphan drug NaMuscla (mexiletine). Medis will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European

countries. NaMuscla is the first and only licensed product for this indication.

Under the agreement, Medis will initially focus on the commercialisation of NaMuscla in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in the first phase. Lupin will continue commercialisation of NaMuscla in Germany, France, and the UK.